| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia (NCT05429905) | KK Women's and Children's Hospital | 2022-07-18 |
| CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol (NCT05648019) | KK Women's and Children's Hospital | 2022-03-15 |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (NCT05043571) | National University Hospital, Singapore | 2021-09-08 |
| TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia (NCT05017883) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-07-01 |
| ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. (NCT05038696) | National University Hospital, Singapore | 2021-04-28 |
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors (NCT04702841) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2020-06-03 |
| TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia (NCT04692948) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-12-09 |
| CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors (NCT04691713) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-09-01 |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (NCT03198546) | Second Affiliated Hospital of Guangzhou Medical University | 2017-07-01 |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. (NCT03267173) | First Affiliated Hospital of Harbin Medical University | 2017-06-15 |